Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nanjing Vazyme Biotech Co., Ltd. (688105.SS)
Nanjing, CN
Nanjing Vazyme Biotech Co., Ltd., a prominent biotechnology firm, specializes in the comprehensive investigation, development, and manufacturing of essential biological components. These core offerings include enzymes, antigens, antibodies, and unique polymer organic compounds. The company's extensive product portfolio encompasses a broad spectrum of scientific research reagents. This range features solutions for advanced techniques such as PCR cloning and point mutation, nucleic acid extraction, reverse transcription, quantitative PCR (qPCR), cell and protein analysis, gene editing applications, and user-friendly instant granule formulations. Furthermore, Vazyme provides sophisticated reagents crucial for high-throughput sequencing library construction, including those for DNA and RNA library preparation, single-cell epigenetics, magnetic bead-based methodologies, quantitative assays, and the effective storage and extraction of cell-free DNA. Complementing these, the company also delivers a variety of biomedical reagents and related services. Vazyme's diverse clientele spans scientific research institutions, specialized high-throughput sequencing service providers, manufacturers of molecular diagnostic reagents, pharmaceutical enterprises, contract research organizations (CROs), hospitals, and other healthcare facilities. Established in 2012, the company maintains its headquarters in Nanjing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.24% | -5.06% | -4.11% | -9.12% | -16.06% | -4.45% | -12.81% | -45.19% | -77.59% | -77.59% | -77.59% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+0.0% Q1'26: +12.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+20.0% Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+5.3% Q1'26: -26.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-2.8% Q1'26: +0.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-2.2% ★ Q1'26: +0.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+17.2% Q1'26: +9.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×14.31× ★ Q1'26: 112.78× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
1.87B
est: 1.83B (+2.4%)
|
3.57B
est: 3.58B (-0.2%)
|
1.29B
est: 1.36B (-5.7%)
|
1.38B
est: 1.37B (+0.5%)
|
1.38B
est: 1.45B (-4.6%)
|
1.60B
1.58B – 1.61B
+10.4% YoY
|
1.87B
1.71B – 2.08B
+17.4% YoY
|
2.28B
2.22B – 2.34B
+21.9% YoY
|
| EBITDA |
799.66M
est: 414.27M (+93.0%)
|
686.09M
est: 811.44M (-15.4%)
|
18.15M
est: 197.29M (-90.8%)
|
65.46M
est: 198.27M (-67.0%)
|
56.88M
est: 208.97M (-72.8%)
|
230.69M
228.89M – 232.49M
+10.4% YoY
|
270.86M
247.25M – 301.14M
+17.4% YoY
|
330.23M
321.44M – 339.01M
+21.9% YoY
|
| EBIT |
768.40M
est: 345.45M (+122.4%)
|
622.72M
est: 676.66M (-8.0%)
|
-79.51M
est: 129.36M (-161.5%)
|
-29.99M
est: 130.00M (-123.1%)
|
-38.57M
est: 137.02M (-128.2%)
|
151.26M
150.08M – 152.44M
+10.4% YoY
|
177.60M
162.12M – 197.45M
+17.4% YoY
|
216.53M
210.77M – 222.29M
+21.9% YoY
|
| Net Income |
678.29M
est: 664.89M (+2.0%)
|
594.25M
est: 632.10M (-6.0%)
|
-70.96M
est: 28.61M (-348.0%)
|
-18.09M
est: 209.74M (-108.6%)
|
-16.97M
est: 17.12M (-199.1%)
|
122.00M
74.19M – 152.08M
+612.6% YoY
|
134.67M
84.52M – 253.55M
+10.4% YoY
|
248.26M
229.48M – 267.03M
+84.3% YoY
|
| SGA |
499.30M
est: 639.34M (-21.9%)
|
818.98M
est: 1.25B (-34.6%)
|
708.87M
est: 429.04M (+65.2%)
|
722.83M
est: 431.18M (+67.6%)
|
—
est: 454.45M (-100.0%)
|
501.68M
497.77M – 505.60M
+10.4% YoY
|
589.04M
537.70M – 654.90M
+17.4% YoY
|
718.15M
699.05M – 737.26M
+21.9% YoY
|
| EPS |
1.87
est: 1.68 (+11.6%)
|
1.49
est: 1.61 (-7.2%)
|
-0.18
est: 0.07 (-369.3%)
|
-0.05
est: 0.49 (-110.2%)
|
-0.04
est: 0.04 (-200.0%)
|
0.27
0.17 – 0.36
+566.7% YoY
|
0.42
0.20 – 0.60
+58.7% YoY
|
0.58
0.54 – 0.63
+37.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 212.3K | 0.06% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 16.0K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 7.1K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 787.7K | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 16.5K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.04M | 0.05% |
| 7 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 1.3K | 0.22% |
| 8 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 3.8K | 0.22% |
| 9 | Vanguard Total World Stock ETF VT | 0.00% | 30.5K | 0.06% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 2.0K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guo Yang Zhang | Chairman of the Supervisory Board & Head of Human Resources Department | — | male |
| Jin Huang | Board Secretary | — | male |
| Kai Shen | Accounting Supervisor | — | — |
| Lijun Zhang | Deputy GM & Director | — | male |
| Lin Cao | Chairman of the Board & GM | — | male |
| Wen Xin Bi | Chief Financial Officer | — | male |
| Xiao Mei Hu | Deputy GM & Director | — | female |
| Xiaoyu Xu | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688105.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
